Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Ceritinib

ec824b75-6f7b-5be1-8112-779889cc75fa · FDA Approved · targets ALK

Ceritinib

MeasuredReference

Ceritinib targets FES_FPS, STK22D_TSSK1, LRRK2. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

FES_FPSSTK22D_TSSK1LRRK2IRR_INSRRFER

Top hallmarks

  • tumor promoting inflammation2.4k
  • proliferation2.3k
  • evading apoptosis2.1k

Top pathways disrupted

  • pi3k akt mtor signaling4.5k
  • apical junction4.2k
  • allograft rejection3.7k

Resistance landscape — Ceritinib

MeasuredReference

3 known oncogenic variants exist on Ceritinib's top targets — see detail for inhibition impact.

Open in new tab